| Literature DB >> 25056394 |
S Nambiar1, K Laessig1, J Toerner2, J Farley2, E Cox2.
Abstract
A decline in antibacterial drug development coupled with emerging bacterial resistance has resulted in limited treatment options. One of the challenges facing antibacterial drug development is appropriate clinical trial designs. Noninferiority trials are appropriate to study new antibacterial drugs for the treatment of serious diseases; superiority trials can be challenging and cannot be the only acceptable trial design to study antibacterial drugs. Our efforts must continue to make new therapies available to meet patient needs.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25056394 DOI： 10.1038/clpt.2014.116
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875